Jiangsu Recbio Technology Co., Ltd. (2179.HK)
HKD 8.0
(2.56%)
HKD 8.0
(2.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -184.18 Million CNY | 82.33% |
| 2022 | -1.04 Billion CNY | 5.73% |
| 2021 | -1.1 Billion CNY | -235.41% |
| 2020 | -329.69 Million CNY | -537.59% |
| 2019 | -51.71 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 150.01 Million CNY | 10.51% |
| 2024 Q1 | 150.01 Million CNY | 181.45% |
| 2023 Q1 | -569.08 Million CNY | 45.41% |
| 2023 FY | -184.18 Million CNY | 82.33% |
| 2023 Q4 | -184.18 Million CNY | 7.41% |
| 2023 Q3 | -198.91 Million CNY | 63.3% |
| 2023 Q2 | -541.96 Million CNY | 4.77% |
| 2022 Q2 | -1.16 Billion CNY | 0.89% |
| 2022 Q1 | -1.17 Billion CNY | -6.16% |
| 2022 FY | -1.04 Billion CNY | 5.73% |
| 2022 Q4 | -1.04 Billion CNY | 1.92% |
| 2022 Q3 | -1.06 Billion CNY | 8.65% |
| 2021 Q4 | -1.1 Billion CNY | -6.28% |
| 2021 FY | -1.1 Billion CNY | -235.41% |
| 2021 Q1 | 684.99 Million CNY | 307.77% |
| 2021 Q3 | -1.04 Billion CNY | 0.0% |
| 2020 Q4 | -329.69 Million CNY | 0.0% |
| 2020 FY | -329.69 Million CNY | -537.59% |
| 2019 FY | -51.71 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -141.182% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 103.497% |